Archive · 1 Jul 2025
Pharma Sector Faces Uncertainty Amid US Policy Shifts
The pharma sector in India is facing worries because of potential new rules and taxes from the US government.
Former President Trump made some decisions that might lower drug prices and increase scrutiny on imported medicines.
These actions have created uncertainty and could hurt the profits of some Indian pharmaceutical companies.
However, companies that make drugs for others, called CDMOs, are seen as a safer bet because they are less affected by these changes.
Analysts say the next two months are crucial for investors to watch the situation.
Investors are cautious about the pharma sector due to potential US policy shifts.
A Nuvama report highlights anxieties about tariffs between India and the United States.
Former US President Trump passed an Executive Order affecting drug pricing.
Proposed tariffs on pharmaceutical imports could be as high as 25 percent.
CDMOs are expected to perform well, as they are less exposed to US policy changes.
- Who
- Investors in the pharma sector.
- What
- The Indian pharma sector faces uncertainty due to potential US policy shifts.
- When
- The next two months are critical.
- Where
- India and the United States.
- Why
- Due to fears of new US tariffs and regulatory changes.
Concerns
Opportunities
Investor Sentiment
Concerns
Potential tariffs and regulatory changes.
Opportunities
CDMOs may offer better investment opportunities.
- Key Concern
- Potential US policy shift
- Tariff Proposal
- Up to 25%
- Affected Companies
- Large-cap pharma
- Positive Outlook
- CDMOs like Aarti Pharmalabs & Jubilant Pharmova
- Policy Impact
- Most Favoured Nation Drug Pricing
